Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | IL1RN | P18510 | 2/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4206687 | 1.00 | GID4 (0.42) | GID4KDM1AIL1RNERAP2ERAP1 | |
| SCHEMBL29983834 | 1.00 | GID4 (0.42) | GID4KDM1AIL1RNERAP2ERAP1 | |
| SCHEMBL17193124 | 1.00 | GID4 (0.42) | GID4KDM1AIL1RNERAP2ERAP1 | |
| Hydrochloric Acid SCHEMBL30302232 | 0.98 | KDM1A (0.42) | GID4KDM1AIL1RNERAP2ERAP1 | |
| Hydrochloric Acid SCHEMBL29145483 | 0.98 | KDM1A (0.42) | GID4KDM1AIL1RNERAP2ERAP1 | |
| SCHEMBL29325347 | 0.95 | GID4 (0.41) | GID4KDM1AIL1RNERAP2ERAP1 | |
| SCHEMBL29325210 | 0.95 | GID4 (0.41) | GID4KDM1AIL1RNERAP2ERAP1 | |
| SCHEMBL12402720 | 0.89 | IL1RN (0.49) | GID4KDM1AIL1RNERAP2ERAP1 | |
| SCHEMBL1879560 | 0.89 | IL1RN (0.49) | GID4KDM1AIL1RNERAP2ERAP1 | |
| SCHEMBL1150600 | 0.89 | IL1RN (0.49) | GID4KDM1AIL1RNERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3994125-B1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230295076-A1 | ACETOPHENONE OXIME COMPOUND AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295076-A1 | ACETOPHENONE OXIME COMPOUND AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| EP-3994125-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2021003295-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021003295-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | GID4 564/4885KDM1A 3414/4885IL1RN 3463/4885 |
| US-20230295076-A1 | ACETOPHENONE OXIME COMPOUND AND APPLICATION THEREOF | CYP11B2, ALDH7A1, CYP11B1 | GID4 4032/4885KDM1A 2239/4885IL1RN 4811/4885 |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | GID4 564/4885KDM1A 3414/4885IL1RN 3463/4885 |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2A, ADRA2C | GID4 2031/4885KDM1A 1956/4885IL1RN 3974/4885 |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | HSD17B3, HSD17B11, HSD17B1 | GID4 564/4885KDM1A 3414/4885IL1RN 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.